Consequences of long‐term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age‐related macular degeneration
Open Access
- 20 April 2014
- journal article
- letter
- Published by Wiley in Acta Ophthalmologica
- Vol. 92 (8), e697-e698
- https://doi.org/10.1111/aos.12417
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration.Albrecht von Graefes Archiv für Ophthalmologie, 2010
- Evaluation of Injection Frequency and Visual Acuity Outcomes for Ranibizumab Monotherapy in Exudative Age-related Macular DegenerationOphthalmology, 2009
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyOphthalmology, 2009
- An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularizationActa Ophthalmologica Scandinavica, 2006